Restoring healthy gut bacteria after donor stem cell transplant
Intestinal microbiome restoration in allogeneic stem cell transplantation
This work tries to restore healthy gut bacteria early after a donor (allogeneic) stem cell transplant to lower complications like graft-versus-host disease and help immune recovery for transplant patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11332270 on NIH RePORTER |
What this research studies
This project offers a way to rebuild healthy gut bacteria soon after an allogeneic stem cell transplant using microbiome-restoring treatments such as fecal microbiota transplantation (FMT). You would receive the microbiome intervention shortly after transplant and provide stool samples so researchers can track changes in your gut bacteria. Clinicians will monitor transplant outcomes, immune recovery, and any episodes of graft-versus-host disease during regular follow-up visits. The team aims to link improved gut bacterial diversity with fewer complications and faster immune reconstitution.
Who could benefit from this research
Good fit: Ideal candidates are people undergoing allogeneic hematopoietic stem cell transplantation who are willing to receive a microbiome-restoring treatment and provide stool samples and clinical follow-up.
Not a fit: People not receiving an allogeneic transplant (for example, autologous transplant recipients), those with uncontrolled infections, or those ineligible for the intervention may not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could reduce life-threatening graft-versus-host disease and improve survival and immune recovery after donor stem cell transplant.
How similar studies have performed: Early, small studies including work from this group have shown that fecal microbiota transplantation can safely restore gut bacterial diversity after allo-HCT, but larger trials are needed to prove clinical benefit.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Ponce, Doris — Sloan-Kettering Inst Can Research
- Study coordinator: Ponce, Doris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.